| Autor: |
Cabré, A., Lázaro, I., Girona, J., Manzanares, J.M., Marimón, F., Plana, N., Guardiola, M., Heras, M., Masana, L. |
| Zdroj: |
Nutrition, Metabolism & Cardiovascular Diseases; May2010, Vol. 20 Issue 4, p243-248, 6p |
| Abstrakt: |
Abstract: Background and aim: Type 2 diabetic patients have an increased prevalence of hypertriglyceridemia. RBP4 has been associated with insulin resistance and hypertriglyceridemia in obesity, the metabolic syndrome and type 2 diabetes. APOA5 is proposed to be a genetic modulator of triglycerides. The aim of this study was to evaluate the relationship between RBP4 plasma levels and lipid disturbances and to determine the impact of the APOA5−1131 T>C variant on this relationship in type 2 diabetic patients. Methods and results: A total of 165 type 2 diabetic patients were included in the study. RBP4 plasma levels and the APOA5−1131 T>C variant were determined and the complete lipid profile was assessed by sequential ultracentrifugation. RBP4 was positively correlated with triglyceride levels in plasma and with all the components of triglyceride-rich lipoproteins. Despite the fact that a statistically significant relationship between the APOA5 genetic variant and RBP4 plasma levels was not found, the hypertriglyceridemic effect of high RBP4 levels was enhanced by the presence of the APOA5−1131 T>C genetic variant. Correlation coefficients were 2-fold higher for TC carriers compared to TT carriers with regard to RBP4 plasma levels and all the components of triglyceride-rich lipoproteins. Those type 2 diabetic patients with high RBP4 plasma concentrations and who were TC carriers showed an increased incidence of hypertriglyceridemia (OR=7.46, P =0.010). Conclusion: RBP4 is associated with hypertriglyceridemia in type 2 diabetic patients. The RBP4 effect is conditioned by the presence of the APOA5−1131 T>C genetic variant. [Copyright &y& Elsevier] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect